Free Technical Research on Agilent Technologies and Three More Medical Research Equities

Stock Research Monitor: CODX, DGX, and BRKR

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on A sign up now at www.wallstequities.com/registration. On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday’s trading session in bearish territories. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Medical Laboratories & Research equities this morning: Agilent Technologies Inc. (NYSE: A), Co-Diagnostics Inc. (NASDAQ: CODX), Quest Diagnostics Inc. (NYSE: DGX), and Bruker Corp. (NASDAQ: BRKR). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Agilent Technologies

On Monday, shares in Santa Clara, California headquartered Agilent Technologies Inc. recorded a trading volume of 1.59 million shares. The stock ended at $64.63, declining 1.70% from the last trading session. The Company’s shares have gained 7.57% in the last twelve months. The stock is trading above its 50-day moving average by 1.46%. Furthermore, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have a Relative Strength Index (RSI) of 55.91. Get the full research report on A for free by clicking below at:

www.wallstequities.com/registration/?symbol=A

Co-Diagnostics

Salt Lake City, Utah headquartered Co-Diagnostics Inc.’s stock finished yesterday’s session 2.06% higher at $3.47. A total volume of 35,345 shares was traded. The Company’s shares have gained 80.73% over the previous three months. The stock is trading above its 200-day moving average by 3.24%. Furthermore, shares of Co-Diagnostics, which intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, have an RSI of 49.45. Get access to our top-rated research, including the free report on CODX at:

www.wallstequities.com/registration/?symbol=CODX

Quest Diagnostics

At the close of trading on Monday, shares in Secaucus, New Jersey headquartered Quest Diagnostics Inc. saw a rise of 0.28%, ending the day at $107.02. The stock recorded a trading volume of 1.06 million shares, which was higher than its three months average volume of 946.99 thousand shares. The Company’s shares have advanced 5.75% in the previous three months. The stock is trading above its 200-day moving average by 5.12%. Moreover, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 39.55.

On July 10th, 2018, research firm Evercore ISI upgraded the Company’s stock rating from ‘In-line’ to ‘Outperform’. Click here to subscribe for a free membership which welcomes you with our report on DGX at:

www.wallstequities.com/registration/?symbol=DGX

Bruker

Billerica, Massachusetts headquartered Bruker Corp.’s shares ended the day 1.10% lower at $30.64 with a total trading volume of 873,752 shares, which was above their three months average of 603.95 thousand shares. The stock has gained 8.23% over the last twelve months. The Company’s shares are trading above their 50-day moving average by 1.11%. Additionally, shares of Bruker, which manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the US, Europe, Asia/Pacific, and internationally, have an RSI of 58.64. To get free access to your research report on BRKR, sign up at:

www.wallstequities.com/registration/?symbol=BRKR

—

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507464